Samsung Biologics Eyes $2.6 Billion IPO in Korea This Year
Samsung Biologics Co Ltd, a contract manufacturer of biotech drugs for global pharmaceutical firms, said it was planning an IPO this year, an offering that analysts have estimated as being worth as much as $2.6 billion.
The IPO is aimed at helping fund an ambitious expansion in production capacity to make it the world's largest contract manufacturer. It plans to pick advisers for the offering in May, amid a likely record year for Seoul IPOs.
Founded in 2011, Samsung Biologics has the third-largest capacity among global contract manufacturers and counts Roche Holding AG (ROG.S) and Bristol-Myers Squibb Co (BMY.N) among its clients.
The IPO is aimed at helping fund an ambitious expansion in production capacity to make it the world's largest contract manufacturer. It plans to pick advisers for the offering in May, amid a likely record year for Seoul IPOs.
Founded in 2011, Samsung Biologics has the third-largest capacity among global contract manufacturers and counts Roche Holding AG (ROG.S) and Bristol-Myers Squibb Co (BMY.N) among its clients.